产品：人IFN-γ酶联免疫试剂盒

货号：EK0373

 Description

Interferon-gamma (IFN-γ) is an inflammatory cytokine that has been implicated in the development of fibrosis in inflamed tissues. The production of IFN-γ, which is under genetic control, can influence the development of fibrosis in lung allografts. IFN-γ is also produced by natural killer (NK) cells and most prominently by CD8 cytotoxic T cells, and it is vital for the control of microbial pathogens. IFN-γ is believed to be crucial for host defense against many infections. Genetically determined variability in IFN-γ and expression might be important for the development of tuberculosis. IFN-γ activates human macrophage oxidative metabolism and antimicrobial activity. In addition to having antiviral activity, IFN-γ has important immunoregulatory functions. IFN-γ plays an important role in the control of neointima proliferation. The standard product used in this kit is recombinant human IFN-γ, consisting of 144 amino acids with the molecular mass of 17 KDa.

ScienCells human IFN-γ ELISA Kit is based on standard sandwich enzyme-linked immune-sorbent assay technology. Human IFN-γ specific monoclonal antibodies are pre-coated onto 8 x 12 divisible strips. The human specific detection monoclonal antibodies are biotinylated. The test samples and biotinylated detection antibodies are subsequently added to the wells and then washed with PBS or TBS buffer. Avidin-Biotin-Peroxidase Complex is added and unbound conjugates are washed away with PBS or TBS buffer. HRP substrate TMB is used to visualize HRP enzymatic reaction. TMB is catalyzed by HRP to produce a blue color product that changes into yellow after adding acidic stop solution. The intensity of yellow is proportional to the amount of human IFN-γ captured in strips.

Product Use

This product is for research use only. It is not approved for use in humans, animals, or in vitro diagnostic procedures.

Storage

Store at 4°C For Frequent use, at -20°C For infrequent use. Avoid multiple Freeze-thaw cycles.

Shipping

Shipped on gel ice.

Reference

1. Awad, M.; Pravica, V.; Perrey, C.; El Gamel, A.; Yonan, N.; Sinnott, P. J.; Hutchinson, I. V. CA repeat allele polymorphism in the first intron of the human interferon-gamma gene is associated with lung allograft fibrosis. Hum.Immunol. 60: 343-346, 1999.
2. Szabo, S. J.; Sullivan, B. M.; Stemmann, C.; Satoskar, A. R.; Sleckman, B. P.; Glimcher, L. H. Distinct effects of T-bet in T(H)1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science 295: 338-342, 2002.
3. Rossouw, M.; Nel, H. J.; Cooke, G. S.; van Helden, P. D.; Hoal, E. G. Association between tuberculosis and a polymorphic NF-kappa-B binding site in the interferon gamma gene. Lancet 361: 1871-1872, 2003.
4. Nathan, C. F.; Murray, H. W.; Wiebe, M. E.; Rubin, B. Y. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J. Exp. Med. 158: 670-689, 1983.
5. Zohlnhofer, D.; Richter, T.; Neumann, F.-J.; Nuhrenberg, T.; Wessely, R.; Brandl, R.; Murr, A.; Klein, C. A.; Baeuerle, P. A. Transcriptome analysis reveals a role of interferon-gamma in human neointima formation. Molec. Cell 7: 1059-1069, 2001
 

如需要其他产品资料请发邮件至wwwfudan@163.com索取

 Sciencell公司产品由上海中乔新舟生物科技有限公司优质供应 

       近几年的新药研发成功率在逐年下降，其根本原因之一就是传统的药物筛选系统是建立在只具有30-40%人类基因群的一系列细胞株上。这样一个有“缺陷型”药物筛选系统所产生的药物用于人体上就会出现许多致命的弱点和不完整性。新一代药物筛选系统是含有一系列近乎完整的人类基因群的原代细胞株。而利用这些原代细胞株所甄别和筛选出来的候选药物，其诊治人类疾病的成功几率将大大增加。这样不但大大节省了新药的开发成本，而且将极大地提高人类的健康质量。这些产品从根本上提高了全球生命医学研究、人类重要疾病药物研发、新药研发的成功率。所以上海中乔新舟生物科技有限公司致力于提供优质原代细胞产品和完善的售后服务。 
     
       美国ScienCell研究实验室（www.sciencellonline.com）成立于1999年，公司总部位于美国加州的圣地亚哥。主要致力于实验室科研用原代细胞、原代细胞专用培养基、原代细胞无血清培养基、干细胞、干细胞培养基、干细胞无血清培养基的研究和开发，在全球拥有众多客户。在国内销售15年来，很多老师应用其产品发表了高质量的SCI文章，凭借着严格的质控和优秀的产品品质，深受广大科研工作者的信赖。

        ScienCell研究实验室生产的原代细胞、原代细胞专用培养基都经过了严格的质量控制，细胞纯度可达98％。其中包括21种人体正常细胞系统，90多种不同细胞类型。大多数细胞在全球唯有ScienCell实验室能够成功分离，产品质量过硬。 确保了实验结果的真实性、重复性和连贯性。

Sciencell公司部分原代细胞目录（如需要其他细胞资料请发邮件至 wwwfudan@163.com索取）： 
       
        中乔新舟www.zqxzbio.com专长于为生物医药领域的医疗机构、研究中心、企业、临床医生等提供课题设计、基金联合申请、实验技术服务、论文相关服务、采购外包等整体服务，目前已经成长为国内领先的转化医学外包品牌。
         中乔新舟的PI团队已经发展到专职PI 20人，联席PI 312人，其中大多数拥有海外背景。截止到2009年3月，以PI或联席PI为第一作者发表SCI 论文1682 篇（总IF 值为5721.82，其中影响因子IF>5.0 的论文216 篇，IF>10.0论文32 篇）。
  
电话：021-51262076                13371892488
Email:wwwfudan@163.com        企业QQ：4000389959  QQ：739782475
网址：www.zqxzbio.com